Actionable news
All posts from Actionable news
Actionable news in BLUE: bluebird bio, Inc.,

Bluebird Bio To Present Immuno-Oncology And Gene Therapy Data At The Asgct 19 Annual Meeting CAMBRIDGE, Mass

The following excerpt is from the company's SEC filing.

. – April 18, 2016 – bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies for cancer, today announced that data from clinical, preclinical, and research and manufacturing programs will be highlighted in ten presentations at the American Society of Gene & Cell Therapy (ASGCT) 19

Annual Meeting, taking place May 4-7, 2016 in Washington, D.C.

Two oral presentations given by bluebird’s academic collaborators will highlight previously presented data from bluebird bio’s ongoing gene therapy clinical trials. David Williams, M.D., chief of hematology/oncology at Boston Children’s Hospital will present interim data from the Starbeam Study of Lenti-D

in cerebral adrenoleukodystrophy, and Marina Cavazzana, M.D., Ph.D., of Hospital Necker, University Paris Descartes, will present interim data from the HGB-205 study of LentiGlobin

in severe sickle cell disease and transfusion-dependent


Eight additional presentations will be featured at the meeting, highlighting progress across the company’s preclinical, research and process development activities.

“As bluebird continues to build a differentiated T cell oncology franchise, we are excited to present three oncology abstracts that highlight our work on the next generation of technology for T cell-based immunotherapy – including methods of generating T cells with sustained anti-tumor activity, small-molecule regulated chimeric antigen receptors (CARs) and genome editing to generate improved CAR T cells,” said Philip Gregory, D.Phil., chief scientific officer, bluebird bio. “From our hematopoietic stem cell programs, we will also share updates in five presentations covering improvements in scalable manufacturing, transduction efficiency and assay development – critical areas for making gene therapy available to more patients.”

The abstracts are now available online on the ASGCT Annual Meeting website.

Details of bluebird bio’s oral presentations are as follows:


A Phase 2/3 Study of the Efficacy and Safety of Ex Vivo Gene Therapy With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy

Abstract Number:


Clinical Trials Spotlight Symposium


Thursday, May 5...